1. Messori, A., Damuzzo, V., Agnoletto, L. et al. A Model-Independent Method to Determine Restricted Mean Survival Time in the Analysis of Survival Curves. SN Compr. Clin. Med. 2, 66–68 (2020). https://doi.org/10.1007/s42399-019-00199-7
  2. Damuzzo V, Agnoletto L, Leonardi L, Chiumente M, Mengato D, Messori A. Analysis of Survival Curves: Statistical Methods Accounting for the Presence of Long-Term Survivors. Front Oncol. 2019;9:453. Published 2019 Jun 4. doi:10.3389/fonc.2019.0045
  3. Chiumente M, Mengato D, Messori A. Tisagenlecleucel in Non-Hodgkin Lymphoma: The Restricted Mean Survival Time as a Tool for Estimating Progression-Free Life Expectancy Better than the Median. Acta Haematol. 2020;143(6):598-599. doi:10.1159/000505891
  4. Messori A, Damuzzo V, Leonardi L, Agnoletto L, Chiumente M, Mengato D. CAR-T Treatment: Determining the Survival Gain in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2020;20(7):490-491. doi:10.1016/j.clml.2020.02.007
  5. Messori A, Chiumente M, Mengato D. Axicabtagene ciloleucel in non-Hodgkin lymphoma: the restricted mean survival time as a tool for estimating progression-free life expectancy better than the median. Ther Adv Med Oncol. 2020;12:1758835920930643. Published 2020 Jun 3. doi:10.1177/1758835920930643
  6. Rivano M, Cancanelli L, Spazio LD, Chiumente M, Mengato D, Messori A. Restricted mean survival time as outcome measure in advanced urothelial bladder cancer: analysis of 4 clinical studies. Immunotherapy. 2021;13(2):95-101. doi:10.2217/imt-2020-0160
  7. Di Spazio L, Cancanelli L, Rivano M, Chiumente M, Mengato D, Messori A. Restricted mean survival time in advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Eur Rev Med Pharmacol Sci. 2021;25(4):1881-1889. doi:10.26355/eurrev_202102_25083
  8. Cancanelli L, Rivano M, Di Spazio L, Chiumente M, Mengato D, Messori A. Efficacy of Immune Checkpoint Inhibitors in Patients with Mismatch Repair-Deficient or Microsatellite Instability-High Metastatic Colorectal Cancer: Analysis of Three Phase-II Trials. Cureus. 2021;13(11):e19893. Published 2021 Nov 25. doi:10.7759/cureus.19893
  9. Cancanelli L, Mengato D, Di Spazio L, Rivano M, Chiumente M, Messori A. Evaluation of maintenance treatment with PARP inhibitors in ovarian carcinoma patients responding to platinum therapy: Use of restricted mean survival time as an index of efficacy. Int J Clin Pharmacol Ther. 2022;60(1):32-35. doi:10.5414/CP204113
  10. Messori A, Rivano M, Mengato D, Cancanelli L, Di Spazio L, Chiumente M. A preliminary estimate of survival gain and cost-effectiveness of CAR-T in adult patients with acute lymphoblastic leukemia. Leuk Lymphoma. 2022;63(5):1261-1264. doi:10.1080/10428194.2021.2022141
  11. Mengato D, Chiumente M, Messori A. Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: the Improvement in Progression-Free Survival Is Small [published online ahead of print, 2022 Jan 17]. J Gastrointest Cancer. 2022;10.1007/s12029-022-00804-4. doi:10.1007/s12029-022-00804-4
  12. Mengato D, Cancanelli L, Rivano M, Chiumente M, Spazio LD, Messori A. First-line chemoimmunotherapy versus chemotherapy in PD-L1-negative patients with non-small-cell lung cancer. Immunotherapy. 2022;14(11):871-877. doi:10.2217/imt-2021-0208